Check Cap (CHEK) Getting Somewhat Favorable Press Coverage, Study Finds

Media headlines about Check Cap (NASDAQ:CHEK) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Check Cap earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.699549803287 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of analysts have weighed in on the company. HC Wainwright decreased their price target on Check Cap from $7.00 to $5.50 and set a “buy” rating for the company in a report on Tuesday, November 28th. Zacks Investment Research upgraded Check Cap from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Monday, January 15th.

Shares of Check Cap (NASDAQ CHEK) traded up $0.01 during trading on Wednesday, reaching $0.76. The company’s stock had a trading volume of 62,000 shares, compared to its average volume of 402,949. Check Cap has a 52-week low of $0.60 and a 52-week high of $2.39. The firm has a market cap of $14.56 and a P/E ratio of -1.25.

ILLEGAL ACTIVITY NOTICE: “Check Cap (CHEK) Getting Somewhat Favorable Press Coverage, Study Finds” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/check-cap-chek-getting-somewhat-favorable-press-coverage-study-finds.html.

Check Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Insider Buying and Selling by Quarter for Check Cap (NASDAQ:CHEK)

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply